[go: up one dir, main page]

MX2014014066A - Compuestos de cromano. - Google Patents

Compuestos de cromano.

Info

Publication number
MX2014014066A
MX2014014066A MX2014014066A MX2014014066A MX2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A MX 2014014066 A MX2014014066 A MX 2014014066A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
alzheimer
disease
preventing
treating diseases
Prior art date
Application number
MX2014014066A
Other languages
English (en)
Inventor
Makoto Inoue
Ryosuke Munakata
Kiyohiro Samizu
Shingo Yamasaki
Hisao Hamaguchi
Hiroaki Tominaga
Yasuhiro Shiina
Lin Hong
Original Assignee
Comentis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comentis Inc filed Critical Comentis Inc
Publication of MX2014014066A publication Critical patent/MX2014014066A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un compuesto que es útil como un ingrediente activo de una composición farmacéutica, en particular una composición farmacéutica para la prevención o tratamiento de trastornos o condiciones asociadas con y/o mediadas por la actividad de ß-secretasa, la hidrólisis de un sitio de ß-secretasa de una proteína precursora ß-amiloide, y/o la acumulación de la proteína ß-amiloide, incluyendo una composición farmacéutica para prevenir o tratar trastornos que incluyen, pero no están limitados a glaucoma, MCI (Deterioro cognitivo leve) o enfermedad de Alzheimer, especialmente, enfermedad de Alzheimer.
MX2014014066A 2012-05-30 2013-05-29 Compuestos de cromano. MX2014014066A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261653321P 2012-05-30 2012-05-30
US201361782038P 2013-03-14 2013-03-14
PCT/US2013/043016 WO2013181202A2 (en) 2012-05-30 2013-05-29 Chromane compounds

Publications (1)

Publication Number Publication Date
MX2014014066A true MX2014014066A (es) 2015-03-19

Family

ID=49674034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014066A MX2014014066A (es) 2012-05-30 2013-05-29 Compuestos de cromano.

Country Status (15)

Country Link
US (2) US8975415B2 (es)
EP (1) EP2854797A4 (es)
JP (1) JP2015518048A (es)
KR (1) KR20150023536A (es)
CN (1) CN104394862A (es)
AR (1) AR091203A1 (es)
AU (1) AU2013267555A1 (es)
BR (1) BR112014029597A2 (es)
CA (1) CA2873678A1 (es)
EA (1) EA026380B1 (es)
HK (1) HK1208817A1 (es)
MX (1) MX2014014066A (es)
SG (1) SG11201407796YA (es)
TW (1) TW201408672A (es)
WO (1) WO2013181202A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091203A1 (es) 2012-05-30 2015-01-21 Astellas Pharma Inc Compuestos de cromano
TW201629025A (zh) * 2014-10-07 2016-08-16 阿斯特捷利康公司 化合物及其作為ｂａｃｅ抑制劑之用途
CN110724135B (zh) * 2019-11-18 2023-04-28 上海医药工业研究院有限公司 一种艾拉普林中间体及其制备方法
CN110713483B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林中间体及艾拉普林的制备方法
CN110818694B (zh) * 2019-11-18 2023-04-21 上海医药工业研究院有限公司 艾拉普林中间体及其应用
CN110790753B (zh) * 2019-11-18 2023-04-07 上海医药工业研究院 艾拉普林对甲苯磺酸盐、其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4484410B2 (ja) 1999-06-28 2010-06-16 オクラホマ メディカル リサーチ ファウンデーション メマプシン２のインヒビターおよびその使用
US20040121947A1 (en) 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
JP4547152B2 (ja) 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
MY149978A (en) 2003-12-15 2013-11-15 Merck Sharp & Dohme Heterocyclic aspartyl protease inhibitors
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
WO2010013794A1 (en) 2008-07-28 2010-02-04 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
WO2010013302A1 (ja) * 2008-07-28 2010-02-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
JP5444240B2 (ja) * 2008-07-28 2014-03-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 スピロアミノジヒドロチアジン誘導体
US8450308B2 (en) * 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
MY148558A (en) * 2008-09-11 2013-04-30 Amgen Inc Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
DK2406240T3 (en) * 2009-03-13 2016-02-01 Vitae Pharmaceuticals Inc INHIBITORS OF BETA-secretase
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
WO2011072064A1 (en) * 2009-12-08 2011-06-16 Array Biopharma Inc. S piro [chroman - 4, 4 ' - imidazol] ones as beta - secretase inhibitors
EP2539322B1 (en) * 2010-02-24 2014-01-01 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
WO2011115938A1 (en) * 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
JP5584352B2 (ja) * 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
WO2011123674A1 (en) * 2010-03-31 2011-10-06 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
AR083169A1 (es) 2010-09-24 2013-02-06 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
WO2012054510A1 (en) 2010-10-19 2012-04-26 Comentis, Inc. Oxadiazole compounds which inhibit beta-secretase activity and methods of use thereof
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
WO2012071279A1 (en) 2010-11-23 2012-05-31 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
AR091203A1 (es) 2012-05-30 2015-01-21 Astellas Pharma Inc Compuestos de cromano
EP2669286A1 (en) 2012-05-31 2013-12-04 Ares Trading S.A. Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20150225386A1 (en) 2015-08-13
EA201492271A1 (ru) 2015-10-30
EP2854797A2 (en) 2015-04-08
BR112014029597A2 (pt) 2017-11-07
TW201408672A (zh) 2014-03-01
US9242973B2 (en) 2016-01-26
AU2013267555A1 (en) 2014-12-04
JP2015518048A (ja) 2015-06-25
AR091203A1 (es) 2015-01-21
SG11201407796YA (en) 2014-12-30
WO2013181202A3 (en) 2014-01-30
CN104394862A (zh) 2015-03-04
CA2873678A1 (en) 2013-12-05
WO2013181202A2 (en) 2013-12-05
HK1208817A1 (en) 2016-03-18
EA026380B1 (ru) 2017-04-28
US20140179695A1 (en) 2014-06-26
US8975415B2 (en) 2015-03-10
KR20150023536A (ko) 2015-03-05
EP2854797A4 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
CR20130264A (es) Compuestos pirimidinona para uso en el tratamiento de enfermedades o condiciones mediadas por lp-pla2
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12014501334A1 (en) Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
MX2014014066A (es) Compuestos de cromano.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
EP2542085A4 (en) COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2016006906A (es) 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas.
WO2012038850A8 (en) Pyrimidones for treatment of potassium channel related diseases
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
GB201206984D0 (en) New therapeutic use
IN2014DN10683A (es)
WO2014172453A3 (en) Novel compositions useful in treating brain-related diseases or disorders and methods using same